JPMorgan Chase & Co. now owns 136,897 shares of the biopharmaceutical company's stock valued at $418,000 after acquiring an additional 88,404 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Puma Biotechnology by 24.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 863,760 shares of the biopharmaceutical company's stock valued at $2,635,000 after acquiring an additional 170,968 shares in the last quarter. Finally, Barclays PLC increased its position in shares of Puma Biotechnology by 13.3% during the fourth quarter. Barclays PLC now owns 88,407 shares of the biopharmaceutical company's stock valued at $270,000 after acquiring an additional 10,386 shares in the last quarter. Institutional investors own 61.29% of the company's stock.